Dr. Deborah Doroshow presents Sandra, a 54-year-old never-smoker diagnosed 14 months ago with stage IVA non-small cell lung cancer (NSCLC), adenocarcinoma subtype.
Second-Line Treatment Selection After Progression on Chemo-Immunotherapy in HER2-Mutant NSCLC
Dr. Doroshow addresses the critical gap that shaped Sandra's treatment trajectory: incomplete upfront molecular testing in community oncology.
This episode examines second-line therapy selection when brain metastases are present in HER2-mutant non-small cell lung cancer.
This episode focuses on practical decision-making for selecting among HER2-directed therapies after progression on chemo-immunotherapy.
This episode examines Dr. Doroshow's approach to safety counseling when selecting among HER2-directed therapies, with particular attention to Sandra's concern about interstitial lung disease risk given prior pembrolizumab exposure.
Dr. Doroshow addresses financial toxicity as a central concern in Sandra's case and broader challenge in HER2-directed therapy access. Sandra has high-deductible Affordable Care Act marketplace plan with $6,000 annual deductible, is currently on medical leave with uncertain prospects for returning to work and is understandably worried about out-of-pocket expenses that reset each calendar year.